Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Core Insights - Adaptive Biotechnologies has entered into two non-exclusive agreements with Pfizer to advance research in rheumatoid arthritis and other immune-related diseases [1] Company Summary - The collaboration with Pfizer aims to leverage Adaptive Biotechnologies' expertise in immune profiling to enhance the understanding and treatment of autoimmune conditions [1] - These deals signify a strategic partnership that may lead to innovative therapeutic solutions in the field of immunology [1] Industry Summary - The agreements highlight the growing interest and investment in research related to autoimmune diseases, particularly rheumatoid arthritis, which affects millions globally [1] - This collaboration reflects a broader trend in the pharmaceutical industry towards partnerships that combine advanced biotechnology with traditional drug development [1]